Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
NCT00324116
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Clinical and angiographic evidence of juxtafoveal or subfoveal choroidal neovascularization secondary to AMD with a total lesion size of less than 2 MPS disc areas
- Best-corrected visual acuity in the study eye greater than 54 letters (ETDRS)
- Women must be using 2 forms of effective contraception
- Adequate hematological, renal and liver functions
- Any atrophy or fibrosis; any retinal hemorrhage measuring more than 1 disc area
- Any extrafoveal choroidal neovascularization
- Any intraocular surgery or thermal laser to the study eye within 3 months of
enrollment
- Previous or concomitant therapy for AMD including PDT with verteporfin (Visudyne) or
subfoveal/non-foveal thermal laser therapy, transpupillary thermotherapy, external
beam radiation, submacular surgery.
- Presence of other causes of choroidal neovascularization, including pathological
myopia, the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and
multifocal choroiditis
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Charlotte, North Carolina
- Los Angeles, California
- Bridgeport, Connecticut
- Hamden, Connecticut
- Fort Myers, Florida
- New Orleans, Louisiana
- Hagerstown, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Royal Oak, Michigan
- Kansas City, Missouri
- Concord, New Hampshire
- Belleville, New Jersey
- Teaneck, New Jersey
- Great Neck, New York
- Lakewood, Ohio
- Oklahoma City, Oklahoma
- Portland, Oregon
- Columbia, South Carolina
- McAllen, Texas
- Burlington, Vermont
- Nagoya, Aichi
- Urayasu, Chiba
- Fukuoka-shi, Fukuoka-ken
- Maebashi, Gunma
- Sapporo, Hokkaido
- Moriguchi, Osaka
- Suita, Osaka
- Otsu, Shiga
- Chiyoda-ku, Tokyo
- Shinjuku-ku, Tokyo
- Fukushima,
- Kyoto,
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions | |||
| Official Title ICMJE | A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions | |||
| Brief Summary | To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart), of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset, subfoveal and/or juxtafoveal choroidal neovascularization. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 4 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Macular Degeneration | |||
| Intervention ICMJE | Drug: pegaptanib sodium (Macugen)
0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks. Other Name: MACUGEN | |||
| Study Arms ICMJE | Experimental: Active
Intervention: Drug: pegaptanib sodium (Macugen) | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 81 | |||
| Original Enrollment ICMJE | 195 | |||
| Actual Study Completion Date ICMJE | August 2008 | |||
| Actual Primary Completion Date | August 2008 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 50 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | France | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00324116 | |||
| Other Study ID Numbers ICMJE | A5751016 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | ITEC GROUP 3 | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | March 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||